Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II trial of prolonged-infusion gemcitabine plus paclitaxel every 2 weeks as first-line treatment for advanced breast cancer
2004-004148-34Phase 2Active
- Sponsor
- José Ignacio Chacón López-Muñiz
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and paclitaxel in breast cancer, sponsored by José Ignacio Chacón López-Muñiz. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Started Dec 2005; status: active.
02
Drugs
gemcitabinepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-004148-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004148-34.